FDA 483 - Amneal Pharmaceuticals Private Ltd. - July 19, 2024

An FDA 483 inspection at Amneal Pharmaceuticals Private Ltd., Parenteral Unit in Ahmedabad, India, conducted from June 10-19, 2024, revealed critical deficiencies in the company's manufacturing processes. The observations highlight inadequate controls over drug product quality and sterility. Key issues include a failure to establish adequate written procedures for production and process controls, evidenced by incomplete airflow visualization studies, pending Aseptic Process Simulations after equipment modifications, and insufficient Performance Qualification studies for critical equipment. Procedures designed to prevent microbiological contamination were found lacking, with disinfectant efficacy studies not mirroring routine application methods and operators utilizing improperly designed goggle-fitted hoods in aseptic areas that could compromise sterility.

Furthermore, the firm's control procedures for validating manufacturing processes were inadequate. This included critical process parameters without defined specification limits, unverified changes to process parameters during validation batches, and a lack of defined yield specifications or deviation investigations for yield discrepancies. Lastly, routine calibration of electronic equipment, specifically filling balances, was deficient, lacking post-batch weight verification and comprehensive periodic calibration for repeatability and accuracy. These observations indicate a need for Amneal Pharmaceuticals to implement robust corrective and preventive actions to ensure full compliance with regulatory standards for pharmaceutical manufacturing.